Home Sitemap Contact us Accessibility Statement Top of the page
  • Teva supply thousands of different medicines

    Medicines and more

    Supplying medicines to treat a wide range of conditions

  • Generic medicines

    From cholesterol reducers and antibiotics to anti infectives and pain relievers

  • Innovative medicines

    Focusing on MS, cancer, Parkinson’s, asthma, pain and more

  • Research and development

    Bringing hope to patients and choice for healthcare professionals

Our key therapy areas

Central Nervous System

Respiratory

Pain

Oncology

Urology

Women's Health

Generic medicines

With over 400 molecules across our range of generic medicines, Teva is the largest supplier of medicines to the NHS.1 At a global level, Teva has one of the broadest medicines pipelines in the industry.

That means we can be in a strong position to bring generic versions of branded medicines to market on the first day of patent protection ending. Generic medicines are typically sold at a substantially lower price to their branded medicine counterparts, as the development process is generally less costly.

Generic medicines bring significant savings to the NHS medicines bill – estimates are that generic medicines save the NHS over £13 billion every year, compared to the cost if their branded equivalents had been dispensed.2 This frees up valuable NHS budgets.

New Therapeutic Entities

The New Therapeutic Entity (NTE) Programme is aimed at identifying and developing new specialty medicines that provide genuine advances on existing therapies by formulating, delivering or using them in a novel way. 

The aim is for this process to generate new specialty products that address an unmet patient need, are based on a known molecule, are formulated, delivered, or used in a novel way.

Examples that are currently being considered include abuse-deterrent opioid tablets for the management of pain, and once-a-month injections to treat certain conditions where currently injections are given daily.

Through the programme, we aim to have identified 50 new products by 2020 and have submitted a number of these for regulatory approval.

See our full range of medicines

1 Data on file
2 http://www.thetimes.co.uk/tto/health/news/article4570428.ece accessed 18.03.16

Teva UK Limited

Are you a healthcare professional?

To access this section of the Teva UK Limited website you need to be a member of the healthcare profession because the materials included in this area of our website are specifically prepared for that audience only.
To understand why that is - please visit: Working in a regulated environment

Please click on the appropriate button below to confirm that you are healthcare professional.
If you are not a healthcare professional, you will be taken to an area of the website that is appropriate for you.

I am a